- Home
- TCBP vs OGEN Comparison
TCBP vs OGEN Comparison
Compare TCBP & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBP
- OGEN
- Stock Information
- Founded
- TCBP 2013
- OGEN 1996
- Country
- TCBP United Kingdom
- OGEN United States
- Employees
- TCBP N/A
- OGEN N/A
- Industry
- TCBP Biotechnology: Biological Products (No Diagnostic Substances)
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- TCBP Health Care
- OGEN Health Care
- Exchange
- TCBP Nasdaq
- OGEN Nasdaq
- Market Cap
- TCBP 5.0M
- OGEN 5.5M
- IPO Year
- TCBP 2022
- OGEN N/A
- Fundamental
- Price
- TCBP $0.38
- OGEN $0.28
- Analyst Decision
- TCBP Strong Buy
- OGEN
- Analyst Count
- TCBP 1
- OGEN 0
- Target Price
- TCBP $2.40
- OGEN N/A
- AVG Volume (30 Days)
- TCBP 3.1M
- OGEN 1.7M
- Earning Date
- TCBP 11-25-2024
- OGEN 11-13-2024
- Dividend Yield
- TCBP N/A
- OGEN N/A
- EPS Growth
- TCBP N/A
- OGEN N/A
- EPS
- TCBP N/A
- OGEN N/A
- Revenue
- TCBP N/A
- OGEN N/A
- Revenue This Year
- TCBP N/A
- OGEN N/A
- Revenue Next Year
- TCBP N/A
- OGEN N/A
- P/E Ratio
- TCBP N/A
- OGEN N/A
- Revenue Growth
- TCBP N/A
- OGEN N/A
- 52 Week Low
- TCBP $0.37
- OGEN $0.25
- 52 Week High
- TCBP $32.70
- OGEN $6.22
- Technical
- Relative Strength Index (RSI)
- TCBP 30.77
- OGEN 38.94
- Support Level
- TCBP $0.37
- OGEN $0.34
- Resistance Level
- TCBP $0.47
- OGEN $0.42
- Average True Range (ATR)
- TCBP 0.10
- OGEN 0.05
- MACD
- TCBP 0.01
- OGEN -0.01
- Stochastic Oscillator
- TCBP 2.65
- OGEN 5.05
About TCBP TC BioPharm (Holdings) plc
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.